Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Single Ascending Dose, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Activity of SAR439459 in Adults With Osteogenesis Imperfecta

Next Previous
Trial Profile

A Phase 1b, Single Ascending Dose, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Activity of SAR439459 in Adults With Osteogenesis Imperfecta

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SAR 439459 (Primary)
  • Indications Osteogenesis imperfecta
  • Focus Adverse reactions
  • Sponsors Sanofi

Most Recent Events

  • 28 Nov 2024 Status changed from recruiting to discontinued.
  • 01 Dec 2023 Planned End Date changed from 13 Dec 2024 to 30 Jun 2025.
  • 01 Dec 2023 Planned primary completion date changed from 13 Dec 2024 to 30 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top